Colon Cancer - Pipeline Review, H2 2017

Date: December 13, 2017
Pages: 773
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C10829AE6C0EN
Leaflet:

Download PDF Leaflet

Colon Cancer - Pipeline Review, H2 2017
Colon Cancer - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer - Pipeline Review, H2 2017, provides an overview of the Colon Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colon Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 12, 41, 5, 163, 21 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 46 and 17 molecules, respectively.

Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Colon Cancer - Overview
Colon Cancer - Therapeutics Development
Colon Cancer - Therapeutics Assessment
Colon Cancer - Companies Involved in Therapeutics Development
Colon Cancer - Drug Profiles
Colon Cancer - Dormant Projects
Colon Cancer - Discontinued Products
Colon Cancer - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Colon Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Products under Development by Companies, H2 2017 (Contd.11), H2 2017
Products under Development by Companies, H2 2017 (Contd.12), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.2), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.6), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.7), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.8), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.6), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.7), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.8), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Colon Cancer - Pipeline by 3-V Biosciences Inc, H2 2017
Colon Cancer - Pipeline by 4P-Pharma SAS, H2 2017
Colon Cancer - Pipeline by Actinium Pharmaceuticals Inc, H2 2017
Colon Cancer - Pipeline by Adamed Sp z oo, H2 2017
Colon Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H2 2017
Colon Cancer - Pipeline by Aduro BioTech Inc, H2 2017
Colon Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H2 2017
Colon Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
Colon Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2017
Colon Cancer - Pipeline by Affimed GmbH, H2 2017
Colon Cancer - Pipeline by AGV Discovery SAS, H2 2017
Colon Cancer - Pipeline by AIMM Therapeutics BV, H2 2017
Colon Cancer - Pipeline by Ambrx Inc, H2 2017
Colon Cancer - Pipeline by Amgen Inc, H2 2017
Colon Cancer - Pipeline by Anavex Life Sciences Corp, H2 2017
Colon Cancer - Pipeline by AndroScience Corp, H2 2017
Colon Cancer - Pipeline by ANP Technologies Inc, H2 2017
Colon Cancer - Pipeline by Aphios Corp, H2 2017
Colon Cancer - Pipeline by Aposense Ltd, H2 2017
Colon Cancer - Pipeline by Aptose Biosciences Inc, H2 2017
Colon Cancer - Pipeline by Asana BioSciences LLC, H2 2017
Colon Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2017
Colon Cancer - Pipeline by Batu Biologics Inc, H2 2017
Colon Cancer - Pipeline by Bayer AG, H2 2017
Colon Cancer - Pipeline by BCN Biosciences LLC, H2 2017
Colon Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017
Colon Cancer - Pipeline by Bicycle Therapeutics Ltd, H2 2017
Colon Cancer - Pipeline by BioCancell Ltd, H2 2017
Colon Cancer - Pipeline by Biogazelle NV, H2 2017
Colon Cancer - Pipeline by Blirt SA, H2 2017
Colon Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Colon Cancer - Pipeline by Can-Fite BioPharma Ltd, H2 2017
Colon Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017
Colon Cancer - Pipeline by Celgene Corp, H2 2017
Colon Cancer - Pipeline by Celprogen Inc, H2 2017
Colon Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2017
Colon Cancer - Pipeline by CrystalGenomics Inc, H2 2017
Colon Cancer - Pipeline by CytomX Therapeutics Inc, H2 2017
Colon Cancer - Pipeline by Cytune Pharma SAS, H2 2017
Colon Cancer - Pipeline by CZ BioMed Corp, H2 2017
Colon Cancer - Pipeline by Debiopharm International SA, H2 2017
Colon Cancer - Pipeline by DEKK-TEC Inc, H2 2017
Colon Cancer - Pipeline by Eli Lilly and Co, H2 2017
Colon Cancer - Pipeline by EntreChem SL, H2 2017
Colon Cancer - Pipeline by EnzymeBioSystems, H2 2017
Colon Cancer - Pipeline by F-star Biotechnology Ltd, H2 2017
Colon Cancer - Pipeline by Felicitex Therapeutics Inc, H2 2017
Colon Cancer - Pipeline by G1 Therapeutics Inc, H2 2017
Colon Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017
Colon Cancer - Pipeline by GlycaNova Norway AS, H2 2017
Colon Cancer - Pipeline by GlycoMimetics Inc, H2 2017
Colon Cancer - Pipeline by Grunenthal GmbH, H2 2017
Colon Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2017
Colon Cancer - Pipeline by Hamlet Pharma AB, H2 2017
Colon Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Colon Cancer - Pipeline by Histogen Inc, H2 2017
Colon Cancer - Pipeline by HitGen LTD, H2 2017
Colon Cancer - Pipeline by Horizon Pharma Plc, H2 2017
Colon Cancer - Pipeline by Hummingbird Bioscience Pte Ltd, H2 2017
Colon Cancer - Pipeline by Idera Pharmaceuticals Inc, H2 2017
Colon Cancer - Pipeline by Immix BioPharma Inc, H2 2017
Colon Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2017
Colon Cancer - Pipeline by Immunomedics Inc, H2 2017
Colon Cancer - Pipeline by Immunotope Inc, H2 2017
Colon Cancer - Pipeline by IMPACT Therapeutics Inc, H2 2017
Colon Cancer - Pipeline by Infinity Pharmaceuticals Inc, H2 2017
Colon Cancer - Pipeline by Innopharmax Inc, H2 2017
Colon Cancer - Pipeline by Intezyne Technologies Inc, H2 2017
Colon Cancer - Pipeline by Ironwood Pharmaceuticals Inc, H2 2017
Colon Cancer - Pipeline by Jasco Pharmaceuticals LLC, H2 2017
Colon Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017
Colon Cancer - Pipeline by JW Pharmaceutical Corp, H2 2017
Colon Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Colon Cancer - Pipeline by Kineta Inc, H2 2017
Colon Cancer - Pipeline by Kringle Pharma Inc, H2 2017
Colon Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
Colon Cancer - Pipeline by Lipocure Ltd, H2 2017
Colon Cancer - Pipeline by Lixte Biotechnology Holdings Inc, H2 2017
Colon Cancer - Pipeline by Lupin Ltd, H2 2017
Colon Cancer - Pipeline by Lymphocyte Activation Technologies SA, H2 2017
Colon Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2 2017
Colon Cancer - Pipeline by MacroGenics Inc, H2 2017
Colon Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017
Colon Cancer - Pipeline by MaxiVAX SA, H2 2017
Colon Cancer - Pipeline by Medicenna Therapeutics Corp, H2 2017
Colon Cancer - Pipeline by Merus NV, H2 2017
Colon Cancer - Pipeline by Microlin Bio Inc, H2 2017
Colon Cancer - Pipeline by Molecular Targeting Technologies Inc, H2 2017
Colon Cancer - Pipeline by MolMed SpA, H2 2017
Colon Cancer - Pipeline by Mologen AG, H2 2017
Colon Cancer - Pipeline by Monopar Therapeutics LLC, H2 2017
Colon Cancer - Pipeline by Multimmune GmbH, H2 2017
Colon Cancer - Pipeline by Nektar Therapeutics, H2 2017
Colon Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2017
Colon Cancer - Pipeline by Novartis AG, H2 2017
Colon Cancer - Pipeline by OncoResponse Inc, H2 2017
Colon Cancer - Pipeline by Oncovir Inc, H2 2017
Colon Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Colon Cancer - Pipeline by Orega Biotech SAS, H2 2017
Colon Cancer - Pipeline by OSE Immunotherapeutics, H2 2017
Colon Cancer - Pipeline by Panacea Pharmaceuticals Inc, H2 2017
Colon Cancer - Pipeline by Patrys Ltd, H2 2017
Colon Cancer - Pipeline by PharmaCyte Biotech Inc, H2 2017
Colon Cancer - Pipeline by Philogen SpA, H2 2017
Colon Cancer - Pipeline by Plexxikon Inc, H2 2017
Colon Cancer - Pipeline by Prosetta Biosciences Inc, H2 2017
Colon Cancer - Pipeline by Provecs Medical GmbH (Inactive), H2 2017
Colon Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H2 2017
Colon Cancer - Pipeline by Qu Biologics Inc, H2 2017
Colon Cancer - Pipeline by Redx Pharma Plc, H2 2017
Colon Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2017
Colon Cancer - Pipeline by Rgenix Inc, H2 2017
Colon Cancer - Pipeline by Sareum Holdings Plc, H2 2017
Colon Cancer - Pipeline by Sierra Oncology Inc, H2 2017
Colon Cancer - Pipeline by Sigma-Tau SpA, H2 2017
Colon Cancer - Pipeline by Sirnaomics Inc, H2 2017
Colon Cancer - Pipeline by Somantix BV, H2 2017
Colon Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2017
Colon Cancer - Pipeline by Spring Bank Pharmaceuticals Inc, H2 2017
Colon Cancer - Pipeline by Starpharma Holdings Ltd, H2 2017
Colon Cancer - Pipeline by Synergys Biotherapeutics Inc, H2 2017
Colon Cancer - Pipeline by Systimmune Inc, H2 2017
Colon Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2017
Colon Cancer - Pipeline by Takis Srl, H2 2017
Colon Cancer - Pipeline by Theravectys SA, H2 2017
Colon Cancer - Pipeline by Tiziana Life Sciences Plc, H2 2017
Colon Cancer - Pipeline by Transgene Biotek Ltd, H2 2017
Colon Cancer - Pipeline by TVAX Biomedical Inc, H2 2017
Colon Cancer - Pipeline by Tyg Oncology Ltd, H2 2017
Colon Cancer - Pipeline by Vaccibody AS, H2 2017
Colon Cancer - Pipeline by Vaccinogen Inc, H2 2017
Colon Cancer - Pipeline by Vault Pharma Inc, H2 2017
Colon Cancer - Pipeline by Vaxenta Biotechnologies, H2 2017
Colon Cancer - Pipeline by Vernalis Plc, H2 2017
Colon Cancer - Pipeline by VG Life Sciences Inc, H2 2017
Colon Cancer - Pipeline by Vivolux AB, H2 2017
Colon Cancer - Pipeline by Yakult Honsha Co Ltd, H2 2017
Colon Cancer - Pipeline by Zenith Epigenetics Ltd, H2 2017
Colon Cancer - Pipeline by ZIOPHARM Oncology Inc, H2 2017
Colon Cancer - Dormant Projects, H2 2017
Colon Cancer - Dormant Projects, H2 2017 (Contd.1), H2 2017
Colon Cancer - Dormant Projects, H2 2017 (Contd.2), H2 2017
Colon Cancer - Dormant Projects, H2 2017 (Contd.3), H2 2017
Colon Cancer - Dormant Projects, H2 2017 (Contd.4), H2 2017
Colon Cancer - Dormant Projects, H2 2017 (Contd.5), H2 2017
Colon Cancer - Dormant Projects, H2 2017 (Contd.6), H2 2017
Colon Cancer - Dormant Projects, H2 2017 (Contd.7), H2 2017
Colon Cancer - Dormant Projects, H2 2017 (Contd.8), H2 2017
Colon Cancer - Dormant Projects, H2 2017 (Contd.9), H2 2017
Colon Cancer - Dormant Projects, H2 2017 (Contd.10), H2 2017
Colon Cancer - Dormant Projects, H2 2017 (Contd.11), H2 2017
Colon Cancer - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Colon Cancer, H2 2017 40
Number of Products under Development by Companies, H2 2017 41
Number of Products under Development by Universities/Institutes, H2 2017 53
Number of Products by Top 10 Targets, H2 2017 74
Number of Products by Stage and Top 10 Targets, H2 2017 74
Number of Products by Top 10 Mechanism of Actions, H2 2017 84
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 84
Number of Products by Routes of Administration, H2 2017 94
Number of Products by Stage and Routes of Administration, H2 2017 94
Number of Products by Top 10 Molecule Types, H2 2017 96
Number of Products by Stage and Top 10 Molecule Types, H2 2017 96

COMPANIES MENTIONED

3-V Biosciences Inc
4P-Pharma SAS
Actinium Pharmaceuticals Inc
Adamed Sp z oo
Adgero Biopharmaceuticals Holdings Inc
Aduro BioTech Inc
Advanced Cancer Therapeutics LLC
Advenchen Laboratories LLC
Aeglea BioTherapeutics Inc
Affimed GmbH
AGV Discovery SAS
AIMM Therapeutics BV
Ambrx Inc
Amgen Inc
Anavex Life Sciences Corp
AndroScience Corp
ANP Technologies Inc
Aphios Corp
Aposense Ltd
Aptose Biosciences Inc
Asana BioSciences LLC
Aurigene Discovery Technologies Ltd
Batu Biologics Inc
Bayer AG
BCN Biosciences LLC
BeyondSpring Pharmaceuticals Inc
Bicycle Therapeutics Ltd
BioCancell Ltd
Biogazelle NV
Blirt SA
Boehringer Ingelheim GmbH
Can-Fite BioPharma Ltd
CBT Pharmaceuticals Inc
Celgene Corp
Celprogen Inc
Critical Outcome Technologies Inc
CrystalGenomics Inc
CytomX Therapeutics Inc
Cytune Pharma SAS
CZ BioMed Corp
Debiopharm International SA
DEKK-TEC Inc
Eli Lilly and Co
EntreChem SL
EnzymeBioSystems
F-star Biotechnology Ltd
Felicitex Therapeutics Inc
G1 Therapeutics Inc
GlaxoSmithKline Plc
GlycaNova Norway AS
GlycoMimetics Inc
Grunenthal GmbH
Halozyme Therapeutics Inc
Hamlet Pharma AB
Hanmi Pharmaceuticals Co Ltd
Histogen Inc
HitGen LTD
Horizon Pharma Plc
Hummingbird Bioscience Pte Ltd
Idera Pharmaceuticals Inc
Immix BioPharma Inc
Immune Pharmaceuticals Inc
Immunomedics Inc
Immunotope Inc
IMPACT Therapeutics Inc
Infinity Pharmaceuticals Inc
Innopharmax Inc
Intezyne Technologies Inc
Ironwood Pharmaceuticals Inc
Jasco Pharmaceuticals LLC
Jiangsu Kanion Pharmaceutical Co Ltd
JW Pharmaceutical Corp
Karyopharm Therapeutics Inc
Kineta Inc
Kringle Pharma Inc
Kyowa Hakko Kirin Co Ltd
Lipocure Ltd
Lixte Biotechnology Holdings Inc
Lupin Ltd
Lymphocyte Activation Technologies SA
MabVax Therapeutics Holdings Inc
MacroGenics Inc
Madrigal Pharmaceuticals Inc.
MaxiVAX SA
Medicenna Therapeutics Corp
Merus NV
Microlin Bio Inc
Molecular Targeting Technologies Inc
MolMed SpA
Mologen AG
Monopar Therapeutics LLC
Multimmune GmbH
Nektar Therapeutics
Northwest Biotherapeutics Inc
Novartis AG
OncoResponse Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
Orega Biotech SAS
OSE Immunotherapeutics
Panacea Pharmaceuticals Inc
Patrys Ltd
PharmaCyte Biotech Inc
Philogen SpA
Plexxikon Inc
Prosetta Biosciences Inc
Provecs Medical GmbH (Inactive)
Provectus Biopharmaceuticals Inc
Qu Biologics Inc
Redx Pharma Plc
Rexahn Pharmaceuticals Inc
Rgenix Inc
Sareum Holdings Plc
Sierra Oncology Inc
Sigma-Tau SpA
Sirnaomics Inc
Somantix BV
Sorrento Therapeutics Inc
Spring Bank Pharmaceuticals Inc
Starpharma Holdings Ltd
Synergys Biotherapeutics Inc
Systimmune Inc
Taiwan Liposome Company Ltd
Takis Srl
Theravectys SA
Tiziana Life Sciences Plc
Transgene Biotek Ltd
TVAX Biomedical Inc
Tyg Oncology Ltd
Vaccibody AS
Vaccinogen Inc
Vault Pharma Inc
Vaxenta Biotechnologies
Vernalis Plc
VG Life Sciences Inc
Vivolux AB
Yakult Honsha Co Ltd
Zenith Epigenetics Ltd
ZIOPHARM Oncology Inc
Skip to top


Colon Carcinoma - Pipeline Review, H1 2014 US$ 2,000.00 Mar, 2014 · 45 pages
Colorectal Cancer - Pipeline Review, 2015 US$ 4,000.00 Oct, 2015 · 258 pages
Rectal Cancer - Pipeline Review, H2 2017 US$ 2,000.00 Aug, 2017 · 128 pages
Ureter Cancer - Pipeline Review, H2 2017 US$ 2,000.00 Oct, 2017 · 144 pages
Head And Neck Cancer - Pipeline Review, H1 2017 US$ 2,500.00 May, 2017 · 1247 pages

Ask Your Question

Colon Cancer - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: